Comparative Pharmacology
Head-to-head clinical analysis: PRISMASOL B22GK 4 0 IN PLASTIC CONTAINER versus PRISMASOL BGK 4 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISMASOL B22GK 4 0 IN PLASTIC CONTAINER versus PRISMASOL BGK 4 3 5 IN PLASTIC CONTAINER.
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER vs PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prismasol B22GK 4/0 is a sterile, bicarbonate-based hemofiltration solution used in continuous renal replacement therapy (CRRT). It replaces electrolytes and buffers in the blood, correcting metabolic acidosis and removing waste products via convection and diffusion. The solution contains bicarbonate as a buffer to maintain acid-base balance.
PRISMASOL BGK 4/3.5 is a hemofiltration solution. It provides electrolytes, buffer (bicarbonate), and glucose to replace fluid and electrolyte losses during continuous renal replacement therapy (CRRT). The solution composition maintains fluid and electrolyte balance, and the bicarbonate buffer helps correct metabolic acidosis. It does not have a classic pharmacological mechanism.
Continuous renal replacement therapy (CRRT): 1.5-2.0 L/h effluent rate, typically administered as continuous venovenous hemofiltration (CVVH) or hemodiafiltration (CVVHDF). Route: intravenous via CRRT circuit. Frequency: continuous infusion.
Continuous renal replacement therapy (CRRT) solution: Administer via central venous access at flow rates typically 1500-4000 mL/h, adjusted to achieve desired electrolyte and acid-base balance. Not directly administered; used as replacement or dialysis fluid.
None Documented
None Documented
Not applicable as a drug; the half-life of infused bicarbonate/lactate in patients is approximately 5–10 minutes for lactate conversion and bicarbonate distribution, but this is not relevant to the solution itself.
The components of PRISMASOL BGK 4/3.5 do not have a classical half-life as they are infused continuously during CRRT. The elimination of electrolytes and buffer is governed by the dialysis prescription and the patient's metabolic rate. For instance, the half-life of exogenous bicarbonate is negligible as it rapidly equilibrates with the body's bicarbonate pool; in contrast, the half-life of potassium during CRRT is typically 2-4 hours depending on the dialysate flow rate and the patient's potassium distribution. However, for the solution itself, its 'half-life' is not applicable.
Prismasol B22GK 4/0 is a dialysis solution containing electrolytes and buffer (bicarbonate/lactate). It is not systemically absorbed; during continuous renal replacement therapy (CRRT), solutes and fluid are removed via hemofiltration/dialysis. The solution components are eliminated by the dialysis membrane and not subject to systemic excretion.
PRISMASOL BGK 4/3.5 is a hemodialysis solution; its components (electrolytes, buffer) are eliminated based on patient's renal function and dialysis clearance. For example, potassium is primarily excreted renally (90%) with minor fecal loss (10%); bicarbonate is converted to CO2 and exhaled (lungs) or renally excreted; chloride follows renal excretion. As the solution is administered during continuous renal replacement therapy (CRRT), the exogenous solutes are removed via the hemodialysis filter, with the percentage of elimination dependent on the dialysis dose and patient's residual renal function. In anuric patients, essentially 100% of the infused solution's components are eliminated via the dialysis circuit.
Category C
Category C
Dialysis Solution
Dialysis Solution